KFU. Card publication. Gene therapy using plasmid DNA encoding bone morphogenetic protein 2 and vascular endothelial growth factor 164 genes for the treatmentof equine proximal suspensory desmitis: case reports

- RUS
- 中文
- ES

GENE THERAPY USING PLASMID DNA ENCODING BONE MORPHOGENETIC PROTEIN 2 AND VASCULAR ENDOTHELIAL GROWTH FACTOR 164 GENES FOR THE TREATMENTOF EQUINE PROXIMAL SUSPENSORY DESMITIS: CASE REPORTS

Form of presentation

Articles in Russian journals and collections

Year of publication

2024

��

��

Authors, employees of KFU

Aymaletdinov Aleksandr Maazovich, author

Zakirova Elena Yurevna, author

Rizvanov Albert Anatolevich, author

Bibliographic description in the original language

Kovac M. Gene therapy using plasmid DNA encoding bone morphogenetic protein 2 and vascular endothelial growth factor 164 genes for the treatmentof equine proximal suspensory desmitis: case reports / M. Kovac, I. V. Berestov, A. M. Aimaletdinov [et al.] // Opera Medica et Physiologica. – 2024. – Vol. 11, No. 2. – P. 74-89. – DOI 10.24412/2500-2295-2024-2-74-89

Annotation

Injury to the proximal part of the equine suspensory ligament (SL), called proximal suspensory desmitis (PSD), commonly causes lameness in horses. PSD is extremely difficult to manage and treat, with present methods often unable to achieve full recovery, especially in chronic cases. The present study was the first to use gene therapy to restore moderate and severe injuries of the proximal suspensory ligament in horses. Plasmid DNA encoding species specific bone morphogenetic protein 2 ( bmp2 ) and vascular endothelial growth factor ( vegf164 ) was injected into the site of proximal suspensory ligament injury, followed by box rest and a controlled exercise program. Clinical observations and ultrasound imaging were used to evaluate effectiveness over a period of 12 months. No negative side effects were observed. Clinical improvements were observed, especially in the forelimb affected horses, by day 30. In horses with chronic hindlimb PSD, few clinical improvements were reported. Echogenicity and the fiber alignment scoring improved but no concomitant changes to cross section area, dorsopalmar thickness or lateromedial width of the proximal suspensory ligament were observed. The transfer of bmp2 and vegf164 genes into the equine PSL exhibited beneficial effects in horses with acute or subacute forms of lesions, primarily in the forelimb.

Keywords

PROXIMAL SUSPENSORY DESMITIS, PLASMID DNA, BONE MORPHOGENETIC PROTEIN 2, VASCULAR ENDOTHELIAL GROWTH FACTOR

The name of the journal

Opera Medica et Physiologica

Please use this ID to quote from or refer to the card

https://repository.kpfu.ru/eng/?p_id=315896&p_lang=2

Resource files

File name	Size (MB)	Format
F_07_Zakirova_74_89.pdf	1,15	pdf	show / download

Full metadata record

Field DC	Value	Language
dc.contributor.author	Aymaletdinov Aleksandr Maazovich	ru_RU
dc.contributor.author	Zakirova Elena Yurevna	ru_RU
dc.contributor.author	Rizvanov Albert Anatolevich	ru_RU
dc.date.accessioned	2024-01-01T00:00:00Z	ru_RU
dc.date.available	2024-01-01T00:00:00Z	ru_RU
dc.date.issued	2024	ru_RU
dc.identifier.citation	Kovac M. Gene therapy using plasmid DNA encoding bone morphogenetic protein 2 and vascular endothelial growth factor 164 genes for the treatmentof equine proximal suspensory desmitis: case reports / M. Kovac, I. V. Berestov, A. M. Aimaletdinov [et al.] // Opera Medica et Physiologica. – 2024. – Vol. 11, No. 2. – P. 74-89. – DOI 10.24412/2500-2295-2024-2-74-89	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/eng/?p_id=315896&p_lang=2	ru_RU
dc.description.abstract	Opera Medica et Physiologica	ru_RU
dc.description.abstract	Injury to the proximal part of the equine suspensory ligament (SL), called proximal suspensory desmitis (PSD), commonly causes lameness in horses. PSD is extremely difficult to manage and treat, with present methods often unable to achieve full recovery, especially in chronic cases. The present study was the first to use gene therapy to restore moderate and severe injuries of the proximal suspensory ligament in horses. Plasmid DNA encoding species specific bone morphogenetic protein 2 ( bmp2 ) and vascular endothelial growth factor ( vegf164 ) was injected into the site of proximal suspensory ligament injury, followed by box rest and a controlled exercise program. Clinical observations and ultrasound imaging were used to evaluate effectiveness over a period of 12 months. No negative side effects were observed. Clinical improvements were observed, especially in the forelimb affected horses, by day 30. In horses with chronic hindlimb PSD, few clinical improvements were reported. Echogenicity and the fiber alignment scoring improved but no concomitant changes to cross section area, dorsopalmar thickness or lateromedial width of the proximal suspensory ligament were observed. The transfer of bmp2 and vegf164 genes into the equine PSL exhibited beneficial effects in horses with acute or subacute forms of lesions, primarily in the forelimb.	ru_RU
dc.language.iso	ru	ru_RU
dc.subject	PROXIMAL SUSPENSORY DESMITIS	ru_RU
dc.subject	PLASMID DNA	ru_RU
dc.subject	BONE MORPHOGENETIC PROTEIN 2	ru_RU
dc.subject	VASCULAR ENDOTHELIAL GROWTH FACTOR	ru_RU
dc.title	Gene therapy using plasmid DNA encoding bone morphogenetic protein 2 and vascular endothelial growth factor 164 genes for the treatmentof equine proximal suspensory desmitis: case reports	ru_RU
dc.type	Articles in Russian journals and collections	ru_RU